Centea Scott

SEC source: 0001140361-23-036118 · form4.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,128

F2 · shares: The exempt disposition of 255 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-23-036118 · form4.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,383

F1 · shares: The exempt disposition of 333 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-23-035727 · form4.xml · derivative · entry 3

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,913

Underlying: Common Stock · 21,913 shares

Expires 2033-07-19

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 19, 2024, such that 25% of the options will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-035727 · form4.xml · derivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,176

Underlying: Common Stock · 21,176 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned over a three-year performance period in accordance with performance metrics as determined by the compensation committee (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-23-035727 · form4.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,716

F1 · shares: The acquisition of 10,588 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 10,588 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 19, 2024, such that 25% of the restricted stock units will vest on each of July 19, 2024, 2025, 2026 and 2027.

SEC source: 0001140361-23-036319 · form4.xml · derivative · entry 3

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,782 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 30,242 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 8,769 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-036319 · form4.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,313

F2 · shares: The exempt disposition of 1,230 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-036319 · form4.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 3,415 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044837 · form4.xml · derivative · entry 3

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,782 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 14, 2020, the reporting person received a target grant of 11,782 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 7,539 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 14, 2020, the reporting person received a target grant of 11,782 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 7,539 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 14, 2020, the reporting person received a target grant of 11,782 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2021, 2022 and 2023. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Based on performance over the period, 7,539 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-23-044837 · form4.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,951

F2 · shares: The exempt disposition of 2,716 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-044837 · form4.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 7,539 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 14, 2020.

SEC source: 0001140361-23-035084 · form4.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,128

F2 · shares: The exempt disposition of 351 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001140361-23-035084 · form4.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,479

F1 · shares: The exempt disposition of 517 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-22-014365 · doc1.xml · derivative · entry 3

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,680

Underlying: Common Stock · 8,680 shares

Expires 2032-07-20

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014365 · doc1.xml · derivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,410

Underlying: Common Stock · 7,410 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-22-014365 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,996

F1 · shares: The acquisition of 3,705 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,705 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-21-019404 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,291

F1 · shares: The exempt disposition of 953 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on October 31, 2019.

SEC source: 0001567619-21-018407 · doc1.xml · derivative · entry 3

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,000 shares

Expires 2024-10-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 10/24/2015, 10/24/2016, 10/24/2017 and 10/24/2018, respectively.

SEC source: 0001567619-21-018407 · doc1.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,244

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $27.99, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-21-018407 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,244

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-014064 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · Sr. VP/GM, Global VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,244

F1 · shares: The exempt disposition of 419 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-21-013923 · doc1.xml · derivative · entry 6

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,721

Underlying: Common Stock · 7,721 shares

Expires 2031-07-21

F6 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013923 · doc1.xml · derivative · entry 5

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,684

Underlying: Common Stock · 5,684 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013923 · doc1.xml · nonDerivative · entry 4

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,663

F4 · shares: The acquisition of 2,842 shares of Common Stock of the Company represents 2,842 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022711 · doc1.xml · derivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,721

Underlying: Common Stock · 7,721 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of performance rights and stock options of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance rights and the exercise price of the options.

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022711 · doc1.xml · derivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,684

Underlying: Common Stock · 5,684 shares

Expires not disclosed

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of performance rights and stock options of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance rights and the exercise price of the options.

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013923 · doc1.xml · nonDerivative · entry 3

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,821

F3 · shares: The exempt disposition of 344 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013923 · doc1.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,165

F2 · shares: The exempt disposition of 339 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013923 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,504

F1 · shares: The exempt disposition of 500 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-20-018615 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,004

F1 · shares: The exempt disposition of 849 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on October 31, 2019.